Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

225
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
225
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

389
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
389
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

611
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
611
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

263
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
263
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

503
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
503
Clinical Trials01:16

Clinical Trials

9.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical acceptability of human challenge trials: Consultation with the US public and with research personnel.

PloS one·2024
Same author

Exploring the ethics of tuberculosis human challenge models.

Journal of medical ethics·2023
Same author

Report From a Multidisciplinary Symposium on the Future of Living Kidney Donor Transplantation.

Progress in transplantation (Aliso Viejo, Calif.)·2023
Same author

Joint statement in support of hepatitis C human challenge studies.

The lancet. Gastroenterology & hepatology·2023
Same author

Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance.

Health security·2023
Same author

Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials.

PloS one·2022

Related Experiment Video

Updated: Oct 9, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.5K

Considering human challenge trials for tuberculosis vaccine development.

Gavriel Kleinwaks1, Virginia Schmit1, Josh Morrison1

  • 11Day Sooner, United States.

Vaccine
|December 19, 2021
PubMed
Summary

Human challenge trials offer a cost-effective and faster approach to vaccine development. For tuberculosis, these trials using attenuated Mycobacterium tuberculosis strains can reduce risks for participants and communities.

Keywords:
Challenge trialControlled human infection modelTuberculosis vaccine

More Related Videos

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K

Related Experiment Videos

Last Updated: Oct 9, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.5K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K

Area of Science:

  • Vaccinology
  • Infectious Disease Research
  • Clinical Trial Design

Background:

  • Vaccine development is costly and time-consuming.
  • Tuberculosis (TB) presents unique challenges for traditional clinical trials.
  • Human challenge trials offer a potential solution to these limitations.

Purpose of the Study:

  • To explore the utility of human challenge trials in accelerating vaccine development.
  • To assess the feasibility and safety of using attenuated Mycobacterium tuberculosis strains in challenge trials for TB vaccine research.

Main Methods:

  • Utilizing fewer participants compared to conventional clinical trials.
  • Reducing the overall time required for trial completion.
  • Employing attenuated strains of Mycobacterium tuberculosis to mitigate risks.

Main Results:

  • Human challenge trials demonstrate improved economic feasibility in vaccine development.
  • Reduced trial duration enhances the efficiency of vaccine research.
  • Attenuated M. tuberculosis strains offer a safer alternative for challenge studies.

Conclusions:

  • Human challenge trials represent a promising and efficient strategy for vaccine development, particularly for diseases like TB.
  • The use of attenuated Mycobacterium tuberculosis strains enhances the safety profile of challenge trials.
  • These trials can significantly impact the development of new TB vaccines.